On the use of hydrogels in cell encapsulation and tissue engineering systems

Recent Patents on Drug Delivery and Formulation

Volumn 2, Issue 1, 2008, Pages 19-24

  Thanos, Christopher G ^a   Emerich, Dwaine F ^b  

^a BROWN UNIVERSITY   (United States)

^b In Cytu Inc   (United States)

Author keywords

Alginate; Biomaterial; Cell therapy; Encapsulation; Hydrogel; Immunoisolation; Scaffold; Tissue engineering; Transplantation

Indexed keywords

ALGINIC ACID; ANTACID AGENT; ANTIDIURETIC AGENT; ARGINYLGLYCYLASPARTIC ACID; BIOMATERIAL; BONE MORPHOGENETIC PROTEIN 2; CHONDROITIN 6 SULFATE; CILIARY NEUROTROPHIC FACTOR; COLLAGEN; COLLAGEN TYPE 2; FERROMAGNETIC MATERIAL; FIBRONECTIN; GELATIN; GLYCOSAMINOGLYCAN; HYALURONIC ACID; LAMININ; MACROGOL; MOLECULAR SCAFFOLD; NERVE GROWTH FACTOR; POLYACRYLIC ACID; POLYAMINE DERIVATIVE; POLYETHYLENE TEREPHTHALATE; POLYMER; POLYORNITHINE; RANITIDINE; RECOMBINANT HUMAN INSULIN;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ARTIFICIAL SKIN; BIOCOMPATIBILITY; CARTILAGE TRANSPLANTATION; CELL ADHESION; CELL DIFFERENTIATION; CELL ENCAPSULATION; CELL METABOLISM; CELL PROLIFERATION; CELL THERAPY; CELL VIABILITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; EXTRACELLULAR MATRIX; EYE DISEASE; GASTROESOPHAGEAL REFLUX; GENE TRANSFER; GENETIC ENGINEERING; HUMAN; HUNTINGTON CHOREA; HYDROGEL; INSULIN DEPENDENT DIABETES MELLITUS; MICROCAPSULE; MICROENCAPSULATION; NERVE FIBER GROWTH; NERVE RECONSTRUCTION; NONHUMAN; PATENT; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REPEATED DRUG DOSE; RETINITIS PIGMENTOSA; TISSUE ENGINEERING; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; VESICOURETERAL REFLUX;

ANIMALS; BIOTECHNOLOGY; CELL PHYSIOLOGICAL PROCESSES; CELL TRANSPLANTATION; HUMANS; HYDROGELS; LIGANDS; PATENTS AS TOPIC; REGENERATIVE MEDICINE; TISSUE ENGINEERING;

EID: 42249099064     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221108783331384     Document Type: Article

References (39)

1. Walker B, Brown B, Krohmer J, Bonte F. Adaptation of disposable plastics to quantitative mammalian cell culture. Tex Rep Biol Med 1962; 20: 682-692.
2. Klebe R. Isolation of a collagen-dependent cell attachment factor. Nature 1974; 19: 248-251.
3. Klebe R. Cell attachment to collagcn: the requirement for energy. J Cell Physiol 1975; 86: 231-6.
4. Ehrmann R, and Gey G. The growth of cells on a transparent gel of reconstituted rat-tail collagen. J Natl Cancer Inst 1956; 16: 1375-403.
5. Yamada K. Cell surface interaction with extracellular materials. Annu Rev Biochem 1983; 52; 761-99.
6. Maroudas N. Chemical and mechanical requirement for fibroblast adhesion. Nature 1973; 244: 353-4.
7. Ruoslahti F., Pierschbacher M. New perspectives in cell adhesion RGD and integrins. Science 1987; 238: 491-7.
8. He H, Cao X, and Lee, L. Design of a novel hydrogel-based intelligent system for controlled drug release. J Control Release 2004; 95: 391-402.
9. Alsberg E, Anderson K, Albeiruti A, Franceschi R, and Mooney D. Cell-interactive alginate hydrogels for bone tissue engineering. J Dent Res 2001; 80: 2025-2029.
10. Leung YF, O'Shea GM, Goosen MF, and Sun AM. Microencapsulation of crystalline insulin or islets of Langerhans: an insulin diffusion study. Artif Organs 1983; 7: 208-212.
11. Emerich D, Winn S, Christenson L, Palmatier M, Gentile F, and Sanberg P. A novel approach to neural transplantation in Parkinson's disease: use of polymer-encapsulated cell therapy. Neurosci Biobehav Rev 1992; 16: 437-47.
12. Sefton M, and Broughton R. Microencapsulation of Erythrocytes. Biochim Biophys Acta 1982; 717: 473-477.
13. Chen J, Fabry B, Schiffrin E, and Wang N. Twisting integrin receptors increases endothelin-1 gene expression in endothelial cells. Am J Physiol Cell Physiol 2001; 280: C1475-84.
14. Yu X, Dillon G, and Bellamkonda R. A laminin and nerve growth factor-laden three-dimensional scaffold for enhanced neurite extension. Tissue Eng 1999; 5: 291-304.
15. Gunn J, Turner S, and Mann B. Adhesive and mechanical properties of hydrogels influence neurite extension. J Biomed Mater Res A 2005; 72: 91-7.
16. Biran R, Webb K, Noble M, and Tresco P. Surfactant-immobilized fibronectin enhances bioactivity and regulates sensory neurite outgrowth. J Biomed Mater Res A 2001; 55: 1-12.
17. Thanos C, Bell W, O'Rourke P, et al. Sustained secretion of ciliary neurotrophic factor to the vitreous, using the encapsulated cell therapy-based NT-501 intraocular device. Tissue Eng 2004; 10: 1617-22.
18. Shepherd B, Enis D, Wang F, Suarez Y, Pober J, and Schechner J. Vascularization and engraftment of human skin substitute using circulating progenitor cell-derived endothelial cells. FASEB J 2006; 20: 1739-41.
19. Tresco P. Tissue engineering strategies for nervous system repair. Prog Brain Res 2000; 128: 349-363.
20. Germain L, Remy-Zolghadri M, and Auger E. Tissue engineering of the vascular system: from capillaries to larger blood vessels. Med Biol Eng Comput 2000; 38: 232-40.
21. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. A phase I study of recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis. Clin Neuropharmacol 1995; 18: 515-532.
22. Aebischer P, Schleup M, Deglon N, et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nature Med 1996; 2: 696-699.
23. Zurn AD, Henry H, Schluep M, et al. Evaluation of an intrathecal immune response in amyotrophic lateral sclerosis patients implanted with encapsulated genetically-engineered xenogeneic cells. Cell Transpl 2000; 9:471-484.
24. Emerich DF, Lindner MD, Winn SR, Chen E-Y, Frydel B, Kordower JH. Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease. J Neurosci 1996; 1: 5168-5181.
25. Kordower JH, Isacson O, Emerich DF. Cellular delivery of trophic factors for the treatment of Huntington's disease: Is neuroprotection possible? Exper Neurol 1999; 59:4-20.
26. Bloch J, Bachoud-Levi AC, Deglon N, et al. Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther 2004; 15: 968-75.
27. Tao W, Wen R, Goddard MB, et al. Incwar. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Ophthalmol Vis Sci 2002; 43: 3292-8.
28. Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor for human retinal degeneration: phase I trial of CNTF-delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci USA 2006; 103: 3896-3901.
29. Thanos CG, Bintz BE, Bell WJ, et al. Intraperitoneal stability of alginate-polyornithine microcapsules in rats: an FTIR aid SEM analysis. Biomaterials 2006; 27: 3570-3579.
30. Thanos CG, Bintz BE, and Emerich DF. Stability of alginate-polyornithine microcapsules is profoundly dependent on the site of transplantation. J Biomed Mater Res A 2007; 81:1-11.
31. Thanos CG, Calafiore R, Basta G, et al. Formulating the alginate-polyornithine biocapsule for prolonged stability: Evaluation of composition and manufacturing technictue. J Biomed Mater Res A 2007; 83:216-224.
32. Elliot RB, Escobar L, Tan PL, et al. Intraperitoneal alginate-encapsulated neonatal porcine islets in a placebo-controlled study with 16 diabetic cynomolgus primates. Transplant Proc 2005; 37: 3505-3508.
33. Mooney, D., Bouhadir, K., Wong, W., Rowley, J.: US20036642363 (2003).
34. Griffith-Cima, L., Atala, A., Vacanti, C., Paige, K.: US5709854 (1998).
35. Hubbell, J.: US6129761 (2000).
36. Vogel, J., Thomas, R., Boschetti, E.: US20067060298 (2006).
37. MacLaughlin, D., Vacanti, J., Donahoe, P., Masiakos, P.: US7078032 (2006).
38. Hammang, J., Baetge, E., Tsiarias, W., Spear, P.: US20036436427 (2003).
39. Geistlich, P., Schloesser, L.: US20077208177 (2007).